Back to top
more

Eiger BioPharmaceuticals, Inc. (EIGR)

(Delayed Data from NSDQ)

$10.50 USD

10.50
381,110

-0.22 (-2.05%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Eiger BioPharmaceuticals, Inc. [EIGR]

Reports for Purchase

Showing records 21 - 40 ( 112 total )

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/19/2020

Company Report

Pages: 8

Q2 Financials - Pipeline Update; Next Zokinvy-/Progeria Nov 20 PDUFA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

06/28/2020

Daily Note

Pages: 14

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

06/04/2020

Company Report

Pages: 8

Q1; Zokinvy Progeria: Priority Review - PDUFA Date Set to November 20, 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

04/28/2020

Company Report

Pages: 7

MAA Validated; We Estimate FDA Acceptance for Review in Q2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

04/03/2020

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

04/03/2020

Company Report

Pages: 8

Delayed Completion of D-LIVR Patient Enrollment Due to COVID-19

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

03/24/2020

Company Report

Pages: 7

NDA Submitted for Lonafarnib/Progeria, We Estimate Potential Launch in 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

03/18/2020

Company Report

Pages: 7

FY19; Progeria NDA Submission end of March; End-of- Treatment LIFT Data at EASL

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

01/06/2020

Company Report

Pages: 7

Lonafarnib/Progeria NDA Submission in Q1; Avexitide/PBH Ph3 Guidance from FDA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

11/14/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

11/14/2019

Company Report

Pages: 9

Q3; Strong Interest in LIFT Data at AASLD; Lonafarnib Progeria NDA by YE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

10/22/2019

Company Report

Pages: 9

Positive Interim End-of-Treatment Results for Phase 2 LIFT in HDV at AASLD

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

08/12/2019

Company Report

Pages: 9

Q2 Financials; Lambda-lonafarnib/HDV End-of-treatment Phase 2 Data at AASLD

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

08/12/2019

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

06/18/2019

Company Report

Pages: 7

Breakthrough Therapy Designation for Avexitide in PBH

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

05/16/2019

Company Report

Pages: 8

Q1 Financials and Regulatory Guidance Upcoming for Avexitide

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

04/24/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

04/23/2019

Company Report

Pages: 9

Financing Extends Runway to Cover Clinical, Regulatory and Commercial Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

04/12/2019

Daily Note

Pages: 9

EASL: Positive End-of-Study Results for Lambda Phase 2 LIMT Study in HDV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Eiger BioPharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

03/28/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party